Recent from talks
Biovail
Knowledge base stats:
Talk channels stats:
Members stats:
Biovail
Biovail Corporation was a Canadian pharmaceutical company, operating internationally in all aspects of pharmaceutical products. Its major production facility was located in Steinbach, Manitoba. It merged with Valeant Pharmaceuticals International in 2010.
As noted in the February 2009 Settlement Agreement with the Ontario Securities Commission: "Biovail admitted that [...] it violated Ontario securities law and engaged in conduct contrary to the public interest."
On September 28, 2010, Biovail merged with Valeant Pharmaceuticals (Bausch Health). The company retained the Valeant name and J. Michael Pearson as CEO, but was incorporated in Canada and temporarily kept Biovail's headquarters.
Biovail’s roots trace back to the 1980s, when Eugene Melnyk, through his company Trimel, pivoted from medical publishing toward pharmaceuticals. In the early 1990s, the firm restructured and adopted the Biovail name, with a strategic focus on drug delivery and controlled-release formulations of established molecules. By concentrating on formulation innovation rather than on de novo drug discovery, Biovail positioned itself to bring incremental improvements to therapies already proven safe and effective.
Following its restructuring, the company aggressively executed its controlled-release strategy through strategic corporate actions in the mid-1990s. On March 29, 1994, the company officially consolidated its corporate architecture by amalgamating Trimel Corporation with its subsidiary to form Biovail Corporation International. During this early foundational period, Biovail secured pivotal development agreements that anchored its commercial pipeline; notably, in June 1993, it entered into a joint product rights agreement with Hoechst-Roussel Pharmaceuticals to co-develop diltiazem-based cardiovascular therapies designed to compete directly with existing market blockbusters. Although this joint venture faced sudden disruption and subsequent litigation when Hoechst AG moved to acquire a competitor in late 1994, a subsequent April 1995 settlement successfully assigned the full New Drug Application (NDA) rights of the flagship drug Tiazac directly to Biovail. This structural milestone legally secured the proprietary foundation for Biovail's first major international commercial rollout and established its signature formulation model.
One of the company’s early commercial successes was the launch of the cardiovascular drug Tiazac (and its once-daily version Tiazac XC) in Canada. Other marketed products included Celexa, Wellbutrin SR/XL, and Retavase, promoted domestically through its Canadian sales arm, Crystaal (later Biovail Pharmaceuticals Canada). These products introduced extended-release or simplified dosing schedules that improved adherence and outcomes for Canadian patients compared with earlier formulations.
Biovail also expanded through licensing agreements and acquisitions, applying its proprietary technologies such as CEFORM®, FlashDose®, and Consurf to improve drug delivery. By leveraging formulation innovation, the company sought to add value without incurring the high costs and risks associated with discovering new chemical entities.
Biovail invested heavily in Canadian operations. Its large manufacturing facility in Steinbach, Manitoba became a major local employer and an important contributor to Canada’s pharmaceutical production base. The company also established its headquarters in Mississauga, Ontario, creating high-skill roles in management, finance, regulatory affairs, and strategy. Together, these sites anchored hundreds of jobs in Canada and provided a platform for training a generation of pharmaceutical professionals, many of whom went on to leadership positions across the Canadian life sciences sector.
Hub AI
Biovail AI simulator
(@Biovail_simulator)
Biovail
Biovail Corporation was a Canadian pharmaceutical company, operating internationally in all aspects of pharmaceutical products. Its major production facility was located in Steinbach, Manitoba. It merged with Valeant Pharmaceuticals International in 2010.
As noted in the February 2009 Settlement Agreement with the Ontario Securities Commission: "Biovail admitted that [...] it violated Ontario securities law and engaged in conduct contrary to the public interest."
On September 28, 2010, Biovail merged with Valeant Pharmaceuticals (Bausch Health). The company retained the Valeant name and J. Michael Pearson as CEO, but was incorporated in Canada and temporarily kept Biovail's headquarters.
Biovail’s roots trace back to the 1980s, when Eugene Melnyk, through his company Trimel, pivoted from medical publishing toward pharmaceuticals. In the early 1990s, the firm restructured and adopted the Biovail name, with a strategic focus on drug delivery and controlled-release formulations of established molecules. By concentrating on formulation innovation rather than on de novo drug discovery, Biovail positioned itself to bring incremental improvements to therapies already proven safe and effective.
Following its restructuring, the company aggressively executed its controlled-release strategy through strategic corporate actions in the mid-1990s. On March 29, 1994, the company officially consolidated its corporate architecture by amalgamating Trimel Corporation with its subsidiary to form Biovail Corporation International. During this early foundational period, Biovail secured pivotal development agreements that anchored its commercial pipeline; notably, in June 1993, it entered into a joint product rights agreement with Hoechst-Roussel Pharmaceuticals to co-develop diltiazem-based cardiovascular therapies designed to compete directly with existing market blockbusters. Although this joint venture faced sudden disruption and subsequent litigation when Hoechst AG moved to acquire a competitor in late 1994, a subsequent April 1995 settlement successfully assigned the full New Drug Application (NDA) rights of the flagship drug Tiazac directly to Biovail. This structural milestone legally secured the proprietary foundation for Biovail's first major international commercial rollout and established its signature formulation model.
One of the company’s early commercial successes was the launch of the cardiovascular drug Tiazac (and its once-daily version Tiazac XC) in Canada. Other marketed products included Celexa, Wellbutrin SR/XL, and Retavase, promoted domestically through its Canadian sales arm, Crystaal (later Biovail Pharmaceuticals Canada). These products introduced extended-release or simplified dosing schedules that improved adherence and outcomes for Canadian patients compared with earlier formulations.
Biovail also expanded through licensing agreements and acquisitions, applying its proprietary technologies such as CEFORM®, FlashDose®, and Consurf to improve drug delivery. By leveraging formulation innovation, the company sought to add value without incurring the high costs and risks associated with discovering new chemical entities.
Biovail invested heavily in Canadian operations. Its large manufacturing facility in Steinbach, Manitoba became a major local employer and an important contributor to Canada’s pharmaceutical production base. The company also established its headquarters in Mississauga, Ontario, creating high-skill roles in management, finance, regulatory affairs, and strategy. Together, these sites anchored hundreds of jobs in Canada and provided a platform for training a generation of pharmaceutical professionals, many of whom went on to leadership positions across the Canadian life sciences sector.